Descemet's Membrane DisorderNCT07364708
AC Deflation in Descemet's Membrane Detachment
A study testing group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection in people with Descemet's Membrane Disorder, run by Minia University at 1 site in Egypt.
Trial summary
using a relatively new technique to manage post-cataract surgery complication and measuring its efficacy Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Descemet's Membrane Disorder
- What is being tested?
- group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Jul 2025to Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with post cataract surgery DM detachment diagnosed within 1st week postoperatively.
- Patient age ranges from 50 to 70 years old.
Who cannot join
- Less than one third of Descemet's Membrane is included.
- Post-operative infection or severe inflammation.
- Patient with pre-existing glaucoma.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Khalafallah
Minya, None Selected, 61111
ahmed Maher khalafallah, 01119094426, drahmedmaher1988@gmail.com
About this study
Official title: Effect of Anterior Chamber Deflation Before Reduction of a Detached Descemet's Membrane
using a relatively new technique to manage post-cataract surgery complication and measuring its efficacy
- Conditions
- Descemet's Membrane Disorder
- Being tested
- group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injectionProcedure or surgery
a group will undergo direct intracameral air injection and another group will undergo anterior chamber deflation then intracameral air injection
| Study group | Role | What they receive |
|---|---|---|
| will undergo direct intracameral air injection | Other | Not described Receives: Procedure: group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection |
| will undergo anterior chamber deflation then intracameral air injection | Other | Not described Receives: Procedure: group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of complete anatomical reduction of DMD on ASOCT at the 1-week visit.
Measured: 1 week
Secondary outcomes (1)
. Time to complete anatomical reduction (days)
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start20 Jul 2025
- Primary completionJan 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Descemet's Membrane DisorderStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Maher Khalafallah, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07364708
- Sponsor's protocol ID
- 592\7\2025
- Status last verified
- Jul 2025
- First submitted
- 29 Dec 2025
- Last updated
- 23 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Anterior Chamber Deflation Before Reduction of a Detached Descemet's Membrane
- ClinicalTrials.gov ID
- NCT07364708
- Acronym / sponsor ID
- 592\7\2025
- Conditions
- Descemet's Membrane Disorder
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 20 Jul 2025 (actual)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
using a relatively new technique to manage post-cataract surgery complication and measuring its efficacy
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| will undergo direct intracameral air injection | Other | Procedure: group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection |
| will undergo anterior chamber deflation then intracameral air injection | Other | Procedure: group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients with post cataract surgery DM detachment diagnosed within 1st week postoperatively.
- Patient age ranges from 50 to 70 years old.
Key exclusion criteria (3 listed)
- Less than one third of Descemet's Membrane is included.
- Post-operative infection or severe inflammation.
- Patient with pre-existing glaucoma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injectiona group will undergo direct intracameral air injection and another group will undergo anterior chamber deflation then intracameral air injection | Procedure or surgery | will undergo anterior chamber deflation then intracameral air injection, will undergo direct intracameral air injection |
Primary outcome
Rate of complete anatomical reduction of DMD on ASOCT at the 1-week visit.
Time frame: 1 week
1 secondary outcome
. Time to complete anatomical reduction (days)
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
- Individual participant dataSharing planned: Yes
Related trials for Descemet's Membrane Disorder
Active, not recruiting
The Belgian Endothelial Surgical Transplant of the Cornea
Corneal Edema, Corneal Endothelial Disorder
RecruitingPhase 2
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy
Not yet recruiting
Partial Range Of Field IOLs in DMEK-Enabled Procedures
Cataract, Fuchs Endothelial Corneal Dystrophy
Recruiting
Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy
Recruiting
Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)
Fuchs Endothelial Corneal Dystrophy, Descemet Membrane Endothelial Keratoplasty (DMEK)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing group A will undergo direct intracameral air injection and group B will undergo anterior chamber deflation then intracameral air injection in people with Descemet's Membrane Disorder, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed Maher Khalafallah (+201119094426, drahmedmaher1988@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of complete anatomical reduction of DMD on ASOCT at the 1-week visit. (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.